A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors
| Autor: | Yongming Chen, Xiaojin Lu, Genyuan Peng, Shengjie Liu, Miao Wang, Huimin Hou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024) |
| Druh dokumentu: | article |
| ISSN: | 21645515 2164-554X 2164-5515 |
| DOI: | 10.1080/21645515.2024.2390727 |
| Popis: | Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are key components in immune checkpoint studies across various tumors, including those in the urinary tract. The utilization of PD-1/PD-L1 inhibitors in urinary tract tumors is on the rise. This study provides a comprehensive overview of PD-1/PD-L1 research in urinary tract tumors through bibliometric analysis. A search was conducted in the Web of Science Core Collection (WoSCC) database for academic papers on PD-1/PD-L1 in urinary tract tumors published between January 1, 1999, and September 3, 2022. Tools such as VOSviewer, CiteSpace, and an online bibliometric platform, were used for an in-depth analysis covering countries, institutions, authors, journals, references, and keywords. A total of 1,711 articles on PD-1/PD-L1 in urinary tract tumors were analyzed. The United States led in article contributions, followed by China and Japan. Harvard University was the top institution in this research area. With notable conctributions from Choueiri TK, who authored 48 related articles. The Journal for Immunotherapy of Cancer was the top publisher, and Topalian SL’s 2012 publication in The New England Journal of Medicine was the most cited article. Key author keywords included “immunotherapy,” “PD-L1,” “renal cell carcinoma,” “bladder cancer,” and “immune checkpoint inhibitors.” Notably, research on the role of PD-1/PD-L1 in kidney and bladder cancer has garnered significant attention. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|